.v3-client-only-control, .v3-contact-form, .amed-client-form { display: none !important; } .v3-logo-track { animation: none !important; } .v3-system-body { grid-template-rows: 1fr !important; } .v3-system-copy { opacity: 1 !important; } [data-v3-home] .reveal, .amed-editorial-page .reveal { opacity: 1 !important; transform: none !important; } .amed-portfolio-group[hidden], .amed-news-archive-card[hidden] { display: block !important; } .amed-fixed-film-firm { opacity: 1 !important; transform: none !important; } .amed-focus-carousel > article { opacity: 1 !important; animation: none !important; } @media (max-width: 1023px) { .v3-menu-button, .v3-header-actions { display: none !important; } .v3-noscript-nav { position: absolute; inset-inline: 0; top: calc(100% + 0.5rem); display: flex !important; padding: 0.75rem 1rem; border: 1px solid rgb(23 53 61 / 0.1); border-radius: 0.625rem; background: rgb(255 255 255 / 0.96); box-shadow: 0 0.75rem 2rem rgb(23 53 61 / 0.1); } }

Skip to content

Venture capital for MedTech innovation

News

PortfolioRejoni Receives FDA Approval of the Juveena® Hydrogel System to Reduce Intrauterine Adhesions Following Hysteroscopic Adhesiolysis29 Sept 2026· Rejoni · businesswire.com

AMEDAMED Ventures’ 2026 Annual LP Meeting Concludes Successfully10 Sep 2026

PortfolioRejoni Secures $25 Million to Accelerate the Juveena Hydrogel System Toward FDA Approval and Launch15 Jun 2026· Rejoni · businesswire.com